Skip to content

Michael H. Baumann

National Institute on Drug Abuse, National Institutes of Health

59 papers in the library · 2,859 citations · publishing 1995-2026

Papers

Sort Most recent Most cited

Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain

Annals of the New York Academy of Sciences October 1, 2004 Michael H. Baumann, Robert D. Clark, Allison G. Budzynski et al. 71 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a popular illicit drug that evokes transporter-mediated release of serotonin (5-HT) and dopamine (DA) from nerve cells. Recently, drug users have ingested combinations of the piperazine analogs, 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP), in an attempt to mimic the subjective effects of MDMA. In the present study, we...

3,4‐methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein

Synapse July 14, 2004 Xiaoying Wang, Michael H. Baumann, Heng Xu et al. 101 citations

Abstract Previous experiments conducted in this laboratory showed that administration of high‐dose D‐fenfluramine (D‐FEN) and p‐chloroamphetamine (PCA) decreased 5‐HT transporter (SERT) binding and tissue 5‐HT by 30–60% in caudate and whole brain tissue 2 days and 2 weeks after drug administration. However, protein expression as determined by Western blot analysis did not change in either...

In Vivo Neurobiological Effects of Ibogaine and Its O-Desmethyl Metabolite, 12-Hydroxyibogamine (Noribogaine), in Rats

Journal of Pharmacology and Experimental Therapeutics May 1, 2001 Michael H. Baumann, Richard B Rothman, John Pablo et al. 69 citations

Ibogaine is a naturally occurring compound with purported antiaddictive properties. When administered to primates, ibogaine is rapidly o-demethylated to form the metabolite 12-hydroxyibogamine (noribogaine). Peak blood levels of noribogaine exceed those of ibogaine, and noribogaine persists in the bloodstream for at least 1 day. Very few studies have systematically evaluated the neurobiological...

Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.

Annals of the New York Academy of Sciences September 1, 2000 Michael H. Baumann, John Pablo, S F Ali et al. 37 citations

Ibogaine (IBO) is a plant-derived alkaloid that is being evaluated as a possible medication for substance use disorders. When administered peripherally to monkeys and humans, IBO is rapidly converted to an o-demethylated metabolite, 12-hydroxyibogamine (NORIBO). We have found in rats that peak blood levels of NORIBO can exceed those of the parent compound, and NORIBO persists in the bloodstream...

Comparative neurobiological effects of ibogaine and MK-801 in rats.

Drug and Alcohol Dependence May 1, 2000 Michael H. Baumann, Richard B Rothman, S F Ali 15 citations

Ibogaine is a plant-derived alkaloid with putative 'anti-addictive' properties. Although ibogaine binds to multiple targets in the brain, recent evidence suggests the drug acts as an N-methyl-D-aspartate (NMDA) antagonist similar to MK-801. The purpose of the present study was to compare neurochemical and neuroendocrine effects of ibogaine and MK-801 in vivo. Male rats received either i.p....

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

Synapse 2000 Richard B Rothman, Michael H. Baumann, Christina M Dersch et al. 933 citations

A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing effects of central nervous system stimulants such as cocaine and amphetamine. The role DA plays in mediating amphetamine-type subjective effects of stimulants in humans remains to be established. Both amphetamine and cocaine increase norepinephrine (NE) via stimulation of...

Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801.

Annals of the New York Academy of Sciences May 1, 1998 Michael H. Baumann, Richard B Rothman, Syed F. Ali 11 citations

Ibogaine (IBO) is a naturally-occurring indole compound that is being evaluated as a potential medication for substance use disorders. Although the precise mechanism of IBO action is unclear, recent in vitro data show this drug displays properties similar to the noncompetitive N-methyl-d-aspartate (NMDA) antagonist MK-801. The purpose of the present work was to compare In Vivo neurobiological...

Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation.

Brain Research October 21, 1996 S F Ali, Glenn D. Newport, William Slikker et al. 29 citations

Ibogaine (IBO) is an indole alkaloid that is reported to facilitate drug abstinence in substance abusers. Despite considerable investigation, the mechanism of IBO action in vivo and its suitability as a treatment for drug addiction remains unclear. The present study was designed to evaluate the time-course effects of acute IBO on neuroendocrine and neurochemical indices. Adult male rats were...

Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.

Life Sciences 1995 Deborah C. Mash, J K Staley, Michael H. Baumann et al. 108 citations

Ibogaine is a hallucinogenic indole with putative efficacy for the treatment of cocaine, stimulant and opiate abuse. The purported efficacy of ibogaine following single dose administrations has led to the suggestion that a long-acting metabolite of ibogaine may explain in part how the drug reduces craving for psychostimulants and opiates. We report here that 12-hydroxyibogamine, a primary...